VLA
VALNEVA
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases.
VALNEVA
VLA
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases.
Anantys Community
Anantys Community
1 member holds VALNEVA with an average return of -34.4%. Join them to follow signals and build your long-term investment strategy.
Price history of VALNEVA
Price history of VALNEVA
Performance & Momentum
Valneva Restructures, Regains Control of Chikungunya Vaccine
Valneva ends its licensing agreement with Serum Institute of India for its Chikungunya vaccine, aiming to regain direct control over supply chain and marketing in at-risk countries. Meanwhile, the company reports positive Phase 2 results showing antibody persistence in children, confirming the full dose for Phase 3. However, Valneva continues consolidation by closing its Nantes site and refocusing French operations in Lyon following a downward revision of its 2025 forecasts. These measures are intended to strengthen operational efficiency and long-term prospects, although the restructuring may cause a transitional period for the stock.
Strategic Analysis
VALNEVA • 2026
Valneva positions itself as a French biotechnology player specializing in vaccines against infectious diseases, combining scientific innovation with clinical expertise. Its niche relies on the development of targeted vaccines with a focus on specific medical needs that are poorly addressed by major pharmaceutical companies.
Strengths
- Specialized expertise in innovative vaccines against emerging infections
- Positioning in a strategic market with high social and health value
- Strengthened European presence enhancing legitimacy in public health programs
Weaknesses
- Marked volatility related to dependence on development cycles and regulatory approvals
- Fragile financial history with long and fluctuating stock performance
Momentum
The recent moderated momentum reflects a partial recovery after a difficult period, underpinned by prospects for commercial recovery. The absence of major news suggests a context of cautious market waiting, where positive developments will depend on clinical and commercial realizations.
Similar stocks to VALNEVA
Recent News
VALNEVA
Valneva Streamlines French Ops, Posts Positive Lyme Vaccine Data
4 months agoValneva is consolidating its French operations by closing its Nantes site and focusing activities in Lyon to boost operational efficiency. The company also reported highly promising Phase 2 results for its Lyme disease vaccine, demonstrating strong antibody responses and good tolerance. Despite first-half 2025 revenue falling short of expectations, Valneva is reaffirming its full-year guidance, supported by these clinical advances and its consolidation strategy.
Valneva's Ixchiq US License Suspended Immediately
7 months agoOn August 25, 2025, Valneva announced that the US FDA has suspended the license for its chikungunya vaccine Ixchiq, resulting in an immediate halt to sales in the United States. This decision, based on updated data from the VAERS system, triggered a sharp 26.33% drop in the stock, reflecting market concerns over the vaccine's commercial and regulatory future. The suspension seriously jeopardizes Valneva's growth prospects in this key segment.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
